The Role of FGFR1 Gene Amplification as a Poor Prognostic Factor in Squamous Cell Lung Cancer: A Meta-Analysis of Published Data

Table 3

RRs of FGFR1 amplification in the studies according to different histology, gender, smoking status, and stage.

	RRs (95% CI)
	Histology; (SQCC versus ADE)	Gender; (M versus F)	Current smokers; versus nonsmokers	Current smokers; versus former smokers	pStage; (III-IV versus I-II)
Seo et al. [29]	5.91 (2.63–13.30)	14.57 (2.01–105.48)	10.81 (3.37–34.63)	—	0.84 (0.39–1.81)
Cihoric et al. [26]	9.46 (2.97–30.09)	2.51 (1.02–6.18)	2.49 (0.36–17.14)	—	—
Toschi et al. [30]	2.45 (1.58–3.80)	1.32 (0.71–2.45)	—	—	1.06 (0.70–1.62)
Russell et al. [31]	13.15 (3.24–53.35)	2.02 (1.07–3.82)	1.25 (0.69–2.26)	1.11 (0.61–2.01)	0.56 (0.27–1.15)
Gadgeel et al. [22]	1.24 (0.45–3.46)	3.95 (0.92–16.98)	2.06 (0.28–15.11)	—	—
Craddock et al. [38]	—	1.94 (0.77–4.90)	0.76 (0.33–1.72)	0.71 (0.31–1.61)	0.62 (0.23–1.69)
Tran et al. [24]	2.19 (1.18–4.05)	1.27 (0.73–2.22)	4.40 (0.29–66.54)	—	1.06 (0.54–2.10)
Kim et al. [25]	—	5.05 (0.32–79.02)	14.97 (4.70–47.71)	—	1.11 (0.55–2.26)
Heist et al. [40]	—	1.60 (0.84–3.01)	0.78 (0.35–1.75)	0.79 (0.35–1.79)	0.94 (0.49–1.83)
Kohler et al. [28]	2.25 (0.67–7.45)	—	—	—	—
Sasaki et al. [23]	—	2.86 (1.10–7.43)	9.79 (1.41–67.97)	—	—
Weiss et al. [27]	—	—	—	—	—
Overall	3.49 (2.62–4.64)	2.03 (1.57–2.63)	2.63 (1.92–3.60)	0.90 (0.59–1.36)	0.90 (0.71–1.15)

RR, relative risk; SQCC, squamous cell lung cancer; ADE, lung adenocarcinoma; M, male; F, female; pStage, pathological stage.
Pathological stage or clinical stage, not specified.